Abstract

Microphysiological systems (MPS) and computer simulation models that recapitulate the underlying biology and toxicology of critical developmental transitions are emerging tools for developmental effects assessment of drugs/chemicals. Opportunities and challenges exist for their application to alternative, more public health relevant and efficient chemical toxicity testing methods. This is especially pertinent to children's health research and the evaluation of complex embryological and reproductive impacts of drug/chemical exposure. Scaling these technologies to higher throughput is a key challenge and drives the need for in silico models for quantitative prediction of developmental toxicity to inform safety assessments. One example is cellular agent-based models, constructed from extant embryology, that produce data useful to simulate critical developmental transitions and thereby predict phenotypic consequences of disruption in silico. Biologically inspired MPS models built from human induced pluripotent stem (iPS)-derived cells and synthetic matrices that recapitulate organ-specific physiologies and native tissue architectures are providing exciting new research opportunities to advance the assessment of developmental toxicity and offer the possibility of deriving a full 'human on a chip' system, or a 'Homunculus.' Impact statement This 'commentary' summarizes research needs and opportunities for engineered MPS models for developmental and reproductive toxicity testing. Emerging concepts can be taken forward to a virtual tissue modeling framework for assessing chemical (and non-chemical) stressors on human development. These models will advance children's health research, both basic and translational and new ways to evaluate complex embryological and reproductive impacts of drug and chemical exposures to inform safety assessments.

Highlights

  • Every 4.5 min a baby is born with a structural birth defect affecting one or more body parts and/or systems

  • Recent investments by the Defense Advanced Research Projects Agency (DARPA), the US Food and Drug Administration (FDA), the National Institutes of Health (NIH), the US Environmental Protection Agency (EPA), and other federal agencies in the US and Europe to support the development of human organ-on-chip and microscale tissue constructs are providing direction on research furthering the ability to assess drug efficacy and chemical toxicity.[1,2]

  • Engineered as microphysiological systems (MPS), these in vitro models provide an environment for empirical testing of chemical safety or drug efficacy in human cell-based tissue constructs using microfluidics that impose realistic fluid-flow and overall complexity of the system to better recapitulate normal biology.[3]

Read more

Summary

Introduction

Every 4.5 min a baby is born with a structural birth defect affecting one or more body parts and/or systems (http:// www.cdc.gov/ncbddd/birthdefects/index.html).

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call